- Home
- Products
- Customized ADCs
- E. coli Stx2A
- Anti-E. coli Stx2A (Setoxaximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC
Anti-E. coli Stx2A (Setoxaximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2485)
This ADC product is comprised of an anti-E. coli Stx2A monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- E. coli Stx2A
- Alternative Names
- E. coli Stx2A
- Overview
- Shiga toxins are a family of related toxins with two major groups, Stx1 and Stx2, expressed by genes considered to be part of the genome of lambdoid prophages. The toxins are named for Kiyoshi Shiga, who first described the bacterial origin of dysentery cMaytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
- Overview
- Anti-E. coli Stx2A IgG1-kappa antibody, Setoxaximab
- Generic name
- Setoxaximab
- Host animal
- Mouse
- Name
- MC-Vc-PAB-DMEA-(PEG2)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- duocarmycin SA
- Description
- Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-TNFRSF17-Mc-MMAF ADC (CAT#: ADC-W-491)
- Anti-EGFR (Nimotuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1063)
- Anti-TNFRSF9 (Urelumab)-SPDB-DM4 ADC (CAT#: ADC-W-1893)
- Anti-ACVR2B (Bimagrumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-655)
- Anti-HIV-1 (Suvizumab)-MC-MMAF ADC (CAT#: ADC-W-2110)
- Anti-NCAM1-SPP-DM1 ADC (CAT#: ADC-W-460)
- Anti-EPCAM (Tucotuzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1086)
- Anti-SLAMF6-Mc-MMAF ADC-1 (CAT#: ADC-W-307)
- Anti-MUC16 (Sofituzumab)-MC-MMAF ADC (CAT#: ADC-W-2567)
- Anti-BSG (Gavilimomab)-SMCC-DM1 ADC (CAT#: ADC-W-716)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2485. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2484 | Anti-E. coli Stx2A (Setoxaximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2480 | Anti-E. coli Stx2A (Setoxaximab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2482 | Anti-E. coli Stx2A (Setoxaximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2481 | Anti-E. coli Stx2A (Setoxaximab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2483 | Anti-E. coli Stx2A (Setoxaximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2547 | Anti-CD44 (Bivatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2615 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2619 | Anti-MS4A1-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2582 | Anti-CEACAM5-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2594 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2588 | Anti-EGFR (Zalutumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2619 | Anti-MS4A1-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2594 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2615 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2564 | Anti-MSLN (Anetumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.